The Apex Times
Above the Noise
Business Wire
BusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessVenezuela’s energy reopening talks could create upside for Chevron and GE Vernova, but agreements still face major hurdlesThe Apex TimesBusinessTrump Says ExxonMobil Is Preparing to Re-enter Venezuela as Investment Outlook ShiftsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessVenezuela’s energy reopening talks could create upside for Chevron and GE Vernova, but agreements still face major hurdlesThe Apex TimesBusinessTrump Says ExxonMobil Is Preparing to Re-enter Venezuela as Investment Outlook ShiftsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessVenezuela’s energy reopening talks could create upside for Chevron and GE Vernova, but agreements still face major hurdlesThe Apex TimesBusinessTrump Says ExxonMobil Is Preparing to Re-enter Venezuela as Investment Outlook ShiftsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessVenezuela’s energy reopening talks could create upside for Chevron and GE Vernova, but agreements still face major hurdlesThe Apex TimesBusinessTrump Says ExxonMobil Is Preparing to Re-enter Venezuela as Investment Outlook ShiftsThe Apex Times
Back to front
Jim Cramer segment highlights Eli Lilly as he indicated he wasn’t selling the drugmaker’s stock
The Apex Times

THE APEX TIMES

Business/The Apex Times/Jun 13, 10:24 AM EDT

Jim Cramer segment highlights Eli Lilly as he indicated he wasn’t selling the drugmaker’s stock

In a Yahoo Finance discussion that touched on SpaceX’s IPO and a basket of names, Eli Lilly and Company (NYSE:LLY) stood out as a holding Cramer said he was not looking to trim.

By The Apex Times Newsroom2 min readAI-assisted Apex article

Eli Lilly and Company (NYSE:LLY) drew attention in a recent Yahoo Finance market segment featuring Jim Cramer, where the host said he was not selling the pharmaceutical stock even while discussing broader market themes and other companies.

The Yahoo Finance piece, titled “Jim Cramer Wasn’t Selling Eli Lilly (LLY),” presented Lilly as one of the 12 stocks Cramer highlighted in the segment. The central takeaway for viewers was the contrast between the usual market chatter about buying and selling and Cramer’s statement that he was not planning to sell his Lilly position, at least in the context of that discussion.

Beyond the headline decision to hold, the post did not provide detailed new operational or financial information about Eli Lilly. It framed Lilly in the context of a stock list Cramer discussed on-air, rather than a fresh catalyst such as earnings results, regulatory action, or trial readouts.

Cramer’s remarks also landed alongside a separate topic in the same broadcast, SpaceX’s IPO discussion. That juxtaposition matters mainly because it indicates how retail investors often process stock narratives in “themes” and “watch lists,” not through company-by-company fundamentals at that moment in time.

From a company and sector perspective, Eli Lilly is widely followed as a large, established healthcare and pharmaceutical company whose stock tends to move on expectations for demand trends, clinical progress across pipelines, and the durability of revenue drivers. In that sense, appearing in Cramer’s “not selling” framing can reinforce that the market view the segment reflects is more about confidence and patience than urgency.

Still, what the Yahoo Finance post did not disclose limits how far investors can responsibly extrapolate. The article description indicates Lilly was one of the 12 stocks discussed and that Cramer said he was not selling, but it does not spell out what specific drivers supported the decision in that moment, nor does it cite particular guidance, trial outcomes, or new regulatory events.

Going forward, the practical question for Lilly-watchers is whether company-specific updates will align with the sentiment implied by the “not selling” message. If Eli Lilly issues new financial guidance, trial updates, or regulatory decisions, those would be the items to monitor next, since they are the kinds of disclosures that typically determine whether market narratives like Cramer’s translate into sustained stock support.

Why It Matters

  • Cramer-style “hold” messaging can influence short-term retail sentiment even without new company fundamentals in the moment.
  • The fact that Lilly appeared in a curated list suggests it remains prominent in mainstream market coverage.
  • Without disclosed Lilly-specific catalysts in the post, investors may need to look for subsequent company releases to validate the sentiment.
  • The juxtaposition with SpaceX’s IPO underscores how market narratives often move together across unrelated sectors.

Sources

Key Facts

  • Jim Cramer was the focus of a Yahoo Finance market segment that highlighted that he was not selling Eli Lilly (LLY).
  • Eli Lilly was included among a list of 12 stocks discussed in that segment.
  • The segment also covered discussion of SpaceX’s IPO, alongside the stock list.
  • The Yahoo Finance post did not, in the information provided here, specify new Lilly-specific financial or clinical catalysts.
  • Eli Lilly is a publicly traded pharmaceutical and healthcare company listed on the NYSE under ticker LLY.

Healthcare Related

Jim Cramer segment highlights Eli Lilly as he indicated he wasn’t selling the drugmaker’s stock | The Apex Times